Jane Osbourn is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery and development of a number of marketed antibody therapies including HUMIRA® (adalimumab) and IMFINZI® (durvalumab).

Jane chairs the Cambridge-based cell therapy company Mogrify, has served as a Director of Babraham Bioscience Technologies, and Cambridge Enterprise, and is a member of the Crick Translational Advisory Group. Previously, she served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel, and from 2015-2019, served as Chair of the Board of Directors of the UK BioIndustry Association.